Bristol Myers Squibb

As part of our commitment to advancing treatments for people living with neurological conditions like #Alzheimers disease, our researchers are exploring how to prevent the spread of tau proteins, which is considered a main driver for disease progression. Learn more about the role of tau in Alzheimer’s disease and why it’s a promising target for disease modification: https://bit.ly/4fmCCHb #CTAD24 #OneBMS

For Dr. Álvaro González Cantero, a practicing dermatologist of 12 years in Madrid, the first visit with his new patients is the most important time to be able to get to know his patients in a meaningful way. This opportunity allows him to understand the physical and emotional impact that psoriasis has on his patients’ day-to-day lives and helps inform their treatment plans moving forward. This #WorldPsoriasisDay, and every day, we are committed to raising awareness for those living with #psorisais, which is often stigmatized, misdiagnosed and undertreated. Hear more psoriasis stories from around the world here: https://bit.ly/4e1fJIX

Our researchers are investigating a potential target known as Factor XIa that may help advance care for people at risk of thrombotic events, like stroke, in our Phase 3 Librexia program with Johnson & Johnson Innovative Medicine. Learn more about the potential of FXIa and how we’re aiming to improve outcomes for patients living with thrombotic conditions: https://bit.ly/3zVT4ix #WorldStrokeDay #OneBMS

We’re looking forward to #PsychCongress2024. Visit booth 709 for the latest information about our neuropsychiatry pipeline and our upcoming presentations at the meeting. Learn more: https://bit.ly/4e3SSvt

We are committed to driving innovations forward that transform care and improve outcomes for patients living with myelodysplastic syndromes (MDS). On #MDSWorldAwarenessDay, we honor the patients, loved ones and healthcare professionals whose shared experiences inform treatment approaches for MDS-related anemia. Learn more about MDS. https://bit.ly/4hlbFFt #MDSAwareness #OneBMS

Today at #ENASymp24 Dr. Jordi Rodón presents in a plenary session, late-breaking updated results from CA240-0007, a Phase 1/2 multiple expansion cohort study of a #PRMT5 inhibitor in patients with advanced #SolidTumors with homozygous #MTAPDeletion. Come explore the exciting data from this potential first-in-class precision medicine for a novel MTAP biomarker. #CancerResearch #SyntheticLethality Don’t miss this exciting presentation in Room 111 + 112 at 15:00 CEST. Learn more below. #LCSM #PancreaticCancer #Mesothelioma #AACR #EORTC #NCI #TripleMeeting https://bit.ly/4hi0Bcg

We are committed to tackling immune-mediated diseases, like #psoriasis, a condition which remains stigmatized and under-researched. Though often recognized by its visible symptoms, psoriasis affects far more than just the skin, impacting the lives of over 100 million people worldwide. Our latest op-ed, “Tackling gaps in Psoriasis care: An imperative for the EU,” explores the urgent need to reduce stigma, improve diagnosis and expand understanding and management of comorbidities through better awareness and shared decision making. The op-ed calls on policymakers to address the ongoing challenges of the disease and stresses the need for Member States to lead the way toward consistent and equitable psoriasis care. Read more: https://bit.ly/4fbYXqH #PsoriaticDiseaseAndFamily #WorldPsoriasisDay

We’re pleased to share memorable moments from the Organization for Latino Achievement (OLA)-led events this Latino & Hispanic Heritage Month, centered on theme “Shaping the future together.” Led by Lorena Kuri, OLA hosted a conversation with Chief Procurement Officer Paula Glickenhaus, a keynote with EVP and Chief Commercialization Officer Adam Lenkowsky with a Ballet Hispanico performance, and a volunteer event for pediatric cancer patients with the Emilio Nares Foundation. Join us in celebrating our OLA colleagues and the impact they’re making on patients and communities around the world!

Explore how we're advancing the future of #CARTcelltherapy by scaling production and enhancing our capabilities to meet growing patient needs. In the latest #DecodedbyBMS article by Thomas Potgieter, he shares how we are committed to ensuring a sustainable and reliable supply as we continue to innovate in cell therapy. https://bit.ly/3Nt6INc